Literature DB >> 1416409

Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.

P Nunn1, R Brindle, L Carpenter, J Odhiambo, K Wasunna, R Newnham, W Githui, S Gathua, M Omwega, K McAdam.   

Abstract

Retrospective studies suggest that the mortality rate from HIV-1-associated tuberculosis is greater than that from tuberculosis alone, but it is not clear if this is due to failure of antituberculosis treatment or to the complications of HIV-1 infection. We have carried out a prospective cohort study of patients with tuberculosis in Nairobi, Kenya, to compare mortality rates, risk factors, and causes of death in HIV-1 positive and HIV-1 negative patients. One hundred seven HIV-1 positive and 174 HIV-1 negative patients with tuberculosis attending two tuberculosis treatment centers in Nairobi were enrolled and followed monthly. Mortality was significantly higher in HIV-1 positive than in HIV-1 negative patients within 6 months of the start of antituberculosis treatment after adjustment for age, sex, and education (rate ratio = 3.8; 95% confidence interval, 1.7 to 8.1; p less than 0.001). Most of the excess mortality occurred after the first month of treatment and was due to nontuberculous infections. Predictors for mortality differed greatly between HIV-1 positive and HIV-1 negative patients. Mortality was greater in HIV-1 positive patients treated with a "standard" regimen for tuberculosis than in HIV-1 positive patients receiving a "short-course" regimen (p = 0.08 when adjusted for all independent risk factors). Tuberculosis control programs in developing countries need to implement "short-course" regimens and train health workers to recognize and treat nontuberculous infections to maintain their effectiveness in the face of the HIV epidemic.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Biology; Causes Of Death; Cohort Analysis; Demographic Factors; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Examinations And Diagnoses; Hiv Infections; Infections; Kenya; Laboratory Examinations And Diagnoses; Mortality; Population; Population Dynamics; Prospective Studies; Research Methodology; Risk Factors; Studies; Treatment; Tuberculosis; Viral Diseases

Mesh:

Substances:

Year:  1992        PMID: 1416409     DOI: 10.1164/ajrccm/146.4.849

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  34 in total

1.  Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

Authors:  Harriet Mayanja-Kizza; Edward Jones-Lopez; Alphonse Okwera; Robert S Wallis; Jerrold J Ellner; Roy D Mugerwa; Christopher C Whalen
Journal:  J Infect Dis       Date:  2005-02-08       Impact factor: 5.226

2.  Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis.

Authors:  Rinat Sergeev; Caroline Colijn; Megan Murray; Ted Cohen
Journal:  Sci Transl Med       Date:  2012-05-23       Impact factor: 17.956

3.  Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients.

Authors:  P Tabarsi; E Chitsaz; A Moradi; P Baghaei; P Farnia; M Marjani; M Shamai; M Amiri; S Nikaein; D Mansouri; M Masjedi; F Altice
Journal:  Int J STD AIDS       Date:  2012-09       Impact factor: 1.359

4.  HIV co-infection with tuberculous and non-tuberculous mycobacteria in western Kenya: challenges in the diagnosis and management.

Authors:  H D N Nyamogoba; G Mbuthia; S Mining; G Kikuvi; R Biegon; S Mpoke; D Menya; P G Waiyaki
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

Review 5.  Tuberculosis and HIV disease: two decades of a dual epidemic.

Authors:  Muktar H Aliyu; Hamisu M Salihu
Journal:  Wien Klin Wochenschr       Date:  2003-10-31       Impact factor: 1.704

6.  Effect of pulmonary tuberculosis on mortality in patients receiving HAART.

Authors:  Daniel Westreich; Patrick MacPhail; Annelies Van Rie; Babatyi Malope-Kgokong; Prudence Ive; Dennis Rubel; Ronan Boulmé; Joseph Eron; Ian Sanne
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

7.  MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis.

Authors:  Michio Kurosu; Dean C Crick
Journal:  Med Chem       Date:  2009-03       Impact factor: 2.745

8.  Effect of free treatment and surveillance on HIV-infected persons who have tuberculosis, Taiwan, 1993-2006.

Authors:  Shu Hui Tseng; Donald Dah Shyong-Jiang; Hao Seong Hoi; Hsiu Yun Lo; Kao Pin Hwang
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

9.  Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa.

Authors:  Kwonjune J Seung; David B Omatayo; Salmaan Keshavjee; Jennifer J Furin; Paul E Farmer; Hind Satti
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

10.  Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand.

Authors:  Somsak Akksilp; Opart Karnkawinpong; Wanpen Wattanaamornkiat; Daranee Viriyakitja; Patama Monkongdee; Walya Sitti; Dhanida Rienthong; Taweesap Siraprapasiri; Charles D Wells; Jordan W Tappero; Jay K Varma
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.